AstraZeneca gets marketing permission for cancer drug in India

New Delhi: AstraZeneca Pharma India on Thursday said it has received approval from the Indian drug regulator to market Durvalumab, a cancer treatment medicine, in the country.

The company has received import and market permission for Durvalumab from the Drug Controller General of India (DCGI), AstraZeneca Pharma India said in a statement.

The approval paves the way for the company to launch the product in the country, it added.

Durvalumab is indicated as a treatment option for patients with locally advanced, unresectable non-small cell lung Cancer (NSCLC) and metastatic urothelial carcinoma.

“The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options,” AstraZeneca Pharma India Managing Director Gagan Singh said.

In India, around one third of patients with NSCLC are present with stage III disease and the company is happy to bring the first immunotherapy into this setting for patients, he added.

  • Related Posts

    8 Women Develop Complications Post C-Section, 2 Critical

    Close on the heels of maternal deaths and kidney-related complications reported in Kota and Bikaner following caesarean deliveries, a similar case has surfaced at Paota District Hospital in Jodhpur, where…

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Jaipur/Kota— In a significant move to strengthen patient safety and improve healthcare delivery in government hospitals, Kota district in-charge secretary Dr. Ravi Kumar Surpur has directed the immediate preparation and effective…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    8 Women Develop Complications Post C-Section, 2 Critical

    8 Women Develop Complications Post C-Section, 2 Critical

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Probe report into maternal deaths sparks Kota row

    Probe report into maternal deaths sparks Kota row

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    CDSCO constitutes consultancy committee for advice on suo motu disclosure

    CDSCO constitutes consultancy committee for advice on suo motu disclosure